VR Adviser
$3.3B 13F equity value
37 Holdings
Quarter ended June 30, 2026
The latest 13F on file for VR Adviser covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| APGE | APOGEE THERAPEUTICS INC | 8,493,321 | $1.1B | 34.2% |
| ORKA | ORUKA THERAPEUTICS INC | 4,148,428 | $395M | 12.0% |
| ERAS | ERASCA INC | 17,891,812 | $328M | 9.9% |
| SYRE | SPYRE THERAPEUTICS INC | 2,985,448 | $265M | 8.0% |
| DNTH | DIANTHUS THERAPEUTICS INC | 1,180,000 | $115M | 3.5% |
| OCUL | OCULAR THERAPEUTIX INC | 10,346,926 | $102M | 3.1% |
| DMRA | DAMORA THERAPEUTICS INC | 3,603,595 | $94M | 2.8% |
| SVRA | SAVARA INC | 14,745,943 | $91M | 2.8% |
| JBIO | JADE BIOSCIENCES INC | 3,220,364 | $72M | 2.2% |
| COGT | COGENT BIOSCIENCES INC | 1,642,166 | $64M | 1.9% |
Track VR Adviser's 13F portfolio: $3.3B in reported holdings, 37 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}